Want to see BMRA full AI Analyst Report?
BMRA Stock Chart & Stats
$2.10
$0.04(2.21%)
At close: 4:00 PM EDT
$2.10
$0.04(2.21%)
Day’s Range― - ―
52-Week Range$1.45 - $3.20
Previous Close$1.6
Volume3.01K
Average Volume (3M)21.51K
Market Cap
$7.90M
Enterprise Value$6.48M
Total Cash (Recent Filing)$2.73M
Total Debt (Recent Filing)$2.33M
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Jan 08, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding4,598,968
10 Day Avg. Volume13,506
30 Day Avg. Volume21,514
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.62
Price to Sales (P/S)1.54
P/FCF Ratio-2.01
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue1.49
Enterprise Value/Gross Profit166.19
Enterprise Value/Ebitda-1.28
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Equity CushionPositive equity and moderate debt relative to assets provide some financial cushion while Biomerica works to improve operations. This does not remove balance-sheet risk, but it may preserve flexibility to pursue its diagnostic business and manage obligations over the next several quarters.
Improving Free Cash Flow TrendThe year-over-year improvement in free cash flow is an encouraging directional change, even though cash generation remains negative. If sustained, better cash performance could reduce funding pressure and provide a foundation for gradual progress toward a self-funding operating model.
Fresh Financing And Institutional AlignmentThe completed financing adds capital to support the company while creating a formal relationship with an institutional investor. Board representation and executive participation may strengthen oversight and alignment, although the new shares also increase the equity base.
Bears Say
Persistent Revenue ContractionSustained revenue contraction limits operating scale and reduces the pool from which Biomerica can fund research, sales efforts, and overhead. Without a durable recovery in product demand, the company may struggle to spread fixed costs and establish a stronger earnings base.
Extremely Thin Margins And Ongoing LossesGross margin below 1% leaves little room to absorb operating expenses or invest behind growth, while recurring EBIT, EBITDA, and net losses show that the business is not yet economically self-sustaining. Margin improvement is therefore essential to durable recovery.
Cash Burn And Rising LeverageContinued operating and free-cash-flow deficits create ongoing funding needs, while rising leverage can reduce financial flexibility. Together, these pressures may constrain investment and increase dependence on external capital unless operating losses and cash consumption materially improve.
Biomerica News
BMRA FAQ
What was Biomerica Inc’s price range in the past 12 months?
Biomerica Inc lowest stock price was $1.45 and its highest was $3.20 in the past 12 months.
What is Biomerica Inc’s market cap?
Biomerica Inc’s market cap is $7.90M.
When is Biomerica Inc’s upcoming earnings report date?
Biomerica Inc’s upcoming earnings report date is Jan 08, 2027 which is in 77 days.
How were Biomerica Inc’s earnings last quarter?
Biomerica Inc released its earnings results on Sep 01, 2026. The company reported -$0.374 earnings per share for the quarter.
Is Biomerica Inc overvalued?
According to Wall Street analysts Biomerica Inc’s price is currently Overvalued.
Does Biomerica Inc pay dividends?
Biomerica Inc does not currently pay dividends.
What is Biomerica Inc’s EPS estimate?
Biomerica Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biomerica Inc have?
Biomerica Inc has 4,598,968 shares outstanding.
What happened to Biomerica Inc’s price movement after its last earnings report?
Biomerica Inc reported an EPS of -$0.374 in its last earnings report. Following the earnings report the stock price went down -1.333%.
Which hedge fund is a major shareholder of Biomerica Inc?
Currently, no hedge funds are holding shares in BMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biomerica Inc
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Technical Analysis
Strata Skin Sciences
―
PAVmed
―
Heart Test Laboratories, Inc.
―
Autonomix Medical, Inc.
―
―
Ownership Overview
11.00% Insiders
4.48% Mutual Funds
<0.01% Other Institutional Investors
84.20% Public Companies and
Individual Investors